Table 4.

Efficacy Outcomes of Eligible Studies

Study	Treatment	Lung NET (n)	PR %	DCR %	Tumor Shrinkage (%)	mPFS (m)	HR	M-fu (m)
Lung subgroup analysis RADIANT-2	EVE 10 mg + OCT LAR 30 mg or placebo + OCT LAR 30 mg	44	0 vs 0	NR	67 vs 27	13.63 vs 5.59	0.72	NR
Lung subgroup analysis RADIANT-4	EVE 10 mg or placebo	90	2 vs 4	81 vs 59	58 vs 13	9.2 vs 3.6	0.50	NR
ITMO 5-Year Update	EVE 10 mg + OCT LAR 30 mg	11	9 (lung NET)	92 (general population)**	NR	33.6 (general population)	NR	50 (general population)
LUNA	PAS or EVE 10 mg or combination	116	2.4 vs 2.4 vs 2.4*	36.5 vs 33.4 vs 51.2*	31 vs 49 vs 73	8.5 vs 12.5 vs 11.8	NR	12

Notes: *Response at month 9. **The authors affirmed that subgroup analyses by tumor primary site did not show any significant difference in ORR.

Abbreviations: DCR, disease control rate (defined as rate of complete, partial and stable responses by radiological assessment, according to criteria employed at the time of the manuscript publication); OCT, octreotide, PAS, pasireotide; PR, partial response; PFS, progression-free survival; HR, hazard ratio; fu, follow-up; EVE, everolimus; NR, not reported.